Switching from Rivaroxaban to Apixaban
When switching from rivaroxaban to apixaban, discontinue rivaroxaban and start apixaban at the time of the next scheduled rivaroxaban dose—no bridging or overlap is needed. 1
Switching Protocol
The FDA-approved apixaban prescribing information provides clear guidance for this transition 1:
- Stop rivaroxaban at your regular dosing time
- Start apixaban at the exact time you would have taken your next rivaroxaban dose
- No gap or overlap between medications is required
- No bridging anticoagulation (such as heparin or enoxaparin) is necessary
Appropriate Apixaban Dosing
The correct apixaban dose depends on your indication:
For Atrial Fibrillation (Stroke Prevention)
- Standard dose: 5 mg twice daily
- Reduced dose: 2.5 mg twice daily if you have at least 2 of the following:
- Age ≥80 years
- Body weight ≤60 kg
- Serum creatinine ≥1.5 mg/dL
For Venous Thromboembolism (DVT/PE Treatment)
- Initial 7 days: 10 mg twice daily
- After 7 days: 5 mg twice daily
- Extended prevention (after ≥6 months): 2.5 mg twice daily
Critical Dosing Distinction
A common and dangerous pitfall: The VTE treatment dose differs from the atrial fibrillation dose. If you're switching for VTE treatment, you must use the higher 10 mg twice daily dose initially, not the 5 mg dose used for atrial fibrillation 5. Using the wrong dose could lead to treatment failure or recurrent thrombosis.
Clinical Outcomes Evidence
Recent high-quality evidence suggests apixaban may offer advantages over rivaroxaban:
For VTE: The 2026 COBRRA trial (n=2,760) demonstrated apixaban had significantly lower clinically relevant bleeding compared to rivaroxaban (3.3% vs 7.1%; relative risk 0.46,95% CI 0.33-0.65, p<0.001) 6
For atrial fibrillation: A 2024 real-world study found that switching from apixaban to rivaroxaban increased stroke/systemic embolism risk (HR 1.99) and major bleeding risk (HR 1.80), while switching from rivaroxaban to apixaban showed similar stroke risk but lower bleeding risk (HR 0.49) 7
Warfarin to DOAC switching: A 2025 nationwide study showed switching from warfarin to apixaban reduced composite outcomes (rate ratio 0.92), while switching to rivaroxaban increased risk (rate ratio 1.08) 8
Timing Considerations
Important caveat: When switching between any anticoagulants, there is a transient increased risk during the first 60 days, followed by risk stabilization thereafter 8. This early transition period requires heightened vigilance for both bleeding and thrombotic complications.
Renal Function Monitoring
Both rivaroxaban and apixaban require dose adjustment for renal impairment, but the thresholds differ 4, 1:
- Rivaroxaban: Dose reduction at CrCl 15-50 mL/min
- Apixaban: Dose reduction based on multiple criteria (age, weight, creatinine) for atrial fibrillation; no specific renal dose adjustment for VTE treatment doses
Verify renal function before switching to ensure appropriate apixaban dosing.
Drug Interactions
If you're taking combined P-glycoprotein and strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir), apixaban doses of 5 mg or 10 mg twice daily should be reduced by 50%. Avoid these inhibitors entirely if already on apixaban 2.5 mg twice daily 1.